TITLE

Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes

AUTHOR(S)
Barber, Katie E.; Werth, Brian J.; Ireland, Cortney E.; Stone, Nicole E.; Nonejuie, Poochit; Sakoulas, George; Pogliano, Joseph; Rybak, Michael J.
PUB. DATE
November 2014
SOURCE
Journal of Antimicrobial Chemotherapy (JAC);Nov2014, Vol. 69 Issue 11, p3006
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objectives Ceftobiprole is a broad-spectrum cephalosporin that demonstrates activity against Staphylococcus aureus resistant to methicillin, including strains with reduced susceptibility to glycopeptides and lipopeptides. The addition of this agent provides a potential therapeutic option for difficult-to-treat infections. Synergy has been demonstrated between β-lactams combined with glycopeptides and lipopeptides against S. aureus. This study sought to determine whether ceftobiprole was synergistic with daptomycin, vancomycin or standard-of-care combination agents (gentamicin or rifampicin) against methicillin-resistant S. aureus (MRSA) strains with varying degrees of vancomycin susceptibility. Methods Broth microdilution MICs of ceftobiprole, daptomycin, vancomycin, rifampicin and gentamicin were evaluated for 20 MRSA isolates. Combination MICs were additionally evaluated in the presence of subinhibitory concentrations of ceftobiprole to assess synergism. Time–kill curves for five representative isolates were performed utilizing combinations of ceftobiprole plus daptomycin, vancomycin, rifampicin and gentamicin to further quantify the degree of synergy for each regimen. Results Ceftobiprole plus daptomycin represented the most potent combination with a 4-fold decrease in MIC and synergy against all strains evaluated in time–kill evaluations. Additionally, binding studies demonstrated enhanced daptomycin binding in the presence of subinhibitory concentrations of ceftobiprole. Conclusions The use of combination therapy with ceftobiprole may provide a needed addition for the treatment of Gram-positive infections resistant to daptomycin or vancomycin. Consistent with what has been observed with other β-lactams, ceftobiprole increased bodipy-tagged daptomycin binding on the surface of S. aureus, potentially explaining this potent synergy observed in time–kill evaluations. More detailed evaluation of ceftobiprole is warranted to better characterize observed synergy.
ACCESSION #
99224344

 

Related Articles

  • Treating Patients With the Best Drugs. Parra-Ruiz, J. // Clinical Infectious Diseases;Oct2013, Vol. 57 Issue 8, p1218 

    A letter to the editor in response to the article "Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections?" by S.J. van Hal and V.G. Fowler in a 2013 issue is presented.

  • Maximize MRSA Management. Bartlett, Jimmy D. // Review of Optometry;11/15/2012, Vol. 149 Issue 11, p26 

    The article focuses on the treatment of methicillin-resistant Staphylococcus aureus (MRSA) that causes ocular infection. It informs about the MRSA's reference to Staphylococcus Aureus pathogens which are resistant to beta lactam. It also includes information on the clinical significance and...

  • Antibacterial and synergic effects of gallic acid- grafted-chitosan with β-lactams against methicillin-resistant Staphylococcus aureus (MRSA). Lee, Dae-Sung; Eom, Sung-Hwan; Kim, Young-Mog; Kim, Hye Seon; Yim, Mi-Jin; Lee, Sang-Hoon; Kim, Do-Hyung; Je, Jae-Young // Canadian Journal of Microbiology;Oct2014, Vol. 60 Issue 10, p629 

    Methicillin-resistant Staphylococcus aureus (MRSA) is spreading worldwide, emphasizing the need to search for new antibiotics. The anti-MRSA activities of gallic acid- grafted-chitosans (GA- g-chitosans) were investigated against 2 MRSA standards and 10 MRSA clinical isolates by determining the...

  • Single-Dose Oritavancin Versus 7–10 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study. Corey, G. Ralph; Good, Samantha; Jiang, Hai; Moeck, Greg; Wikler, Matthew; Green, Sinikka; Manos, Paul; Keech, Richard; Singh, Rajesh; Heller, Barry; Bubnova, Natalia; O'Riordan, William // Clinical Infectious Diseases;Jan2015, Vol. 60 Issue 2, p254 

    A single 1200-mg dose of oritavancin was noninferior to 7–10 days of vancomycin for treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by gram-positive pathogens. Oritavancin provides a single-dose alternative to multi-dose therapies for ABSSSI.Background....

  • New agents approved for treatment of acute staphylococcal skin infections. Tatarkiewicz, Jan; Bujalska-Zadrożny, Magdalena; Staniszewska, Anna // Archives of Medical Science;2016, Vol. 12 Issue 6, p1327 

    Vancomycin has been a predominant treatment for methicillin-resistant Staphylococcus aureus (MRSA) infections for decades. However, growing reservations about its efficacy led to an urgent need for new antibiotics effective against MRSA and other drug-resistant Staphylococcus aureus strains....

  • Combination of Vancomycin and β-Lactam Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: A Pilot Multicenter Randomized Controlled Trial. Davis, Joshua S.; Sud, Archana; O'Sullivan, Matthew V. N.; Robinson, James O.; Ferguson, Patricia E.; Hong Foo; van Ha, Sebastiaan J.; Ralph, Anna P.; Howden, Benjamin P.; Binks, Paula M.; Kirby, Adrienne; Tong, Steven Y. C. // Clinical Infectious Diseases;1/15/2016, Vol. 62 Issue 2, p173 

    Background: In vitro laboratory and animal studies demonstrate a synergistic role for the combination of vancomycin and antistaphylococcal β-lactams for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. Prospective clinical data are lacking. Methods: In this open-label,...

  • Marinopyrrole Derivatives as Potential Antibiotic Agents against Methicillin-Resistant Staphylococcus aureus (II). Cheng, Chunwei; Song, Hao; Liu, Yan; Li, Rongshi; Pan, Lili; Li, Jerry; Qin, Yong // Marine Drugs;Aug2013, Vol. 11 Issue 8, following p2927 

    Methicillin-resistant Staphylococcus aureus (MRSA) continues to be a major problem, causing severe and intractable infections worldwide. MRSA is resistant to all beta-lactam antibiotics, and alternative treatments are limited. A very limited number of new antibiotics have been discovered over...

  • Resistencia a antibióticos de última línea en cocos Gram positivos: la era posterior a la vancomicina. Rincón, Sandra; Panesso, Diana; Díaz, Lorena; Carvajal, Lina P.; Reyes, Jinnethe; Munita, José M.; Arias, César A. // Biomédica: Revista del Instituto Nacional de Salud;2014 Supplement 1, Vol. 34 Issue S1, p191 

    New therapeutic alternatives have been developed in the last years for the treatment of multidrug-resistant Gram-positive infections. Infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) are considered a therapeutic challenge due to...

  • Trimethoprim-Sulfamethoxazole Versus Vancomycin for MRSA Infections.  // Clinical Infectious Diseases;9/1/2015, Vol. 61 Issue 5, piii 

    The article presents a study by M. Paul and colleagues on the use of trimethoprim-sulfamethoxazole and vancomycin for infections caused by meticillin resistant Staphylococcus aureus (MRSA). It mentions that patients with bone or joint infection, soft tissue infection and bacteremia were...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics